The Vyra COVID-19 Antigen Test has been designed for detecting the SARS-CoV-2 virus in the swab samples. Credit: Elchinator / Pixabay.

Canadian diagnostics firm MedMira has obtained the CE mark for its Vyra COVID-19 Antigen Test.

The test has been designed to detect the SARS-CoV-2 virus in the swab samples.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MedMira has developed the rapid antigen test using its patented Rapid Vertical Flow (RVF) technology.

This test expands the current Covid-19 product family and addresses the need for a quick, reliable, and easy-to-use testing solution.

The test is designed to be non-invasive and user-friendly to make it more suitable for any settings.

The Vyra COVID-19 Antigen Test is currently available in Europe as well as in countries that accept the CE mark.

MedMira CEO Hermes Chan said: “Whereas VYRA COVID-19 provides a high-quality single antigen test for the detection of SARS-CoV-2 designed for customers who are worried about a Covid-19 infection, our upcoming VYRA CoV2Flu Antigen Test will further complement our product offering to customers who wish to have a result for Covid-19 or Flu A or Flu B immediately.

“With the increasing infection rates during the next few months and the need for quality rapid testing solutions, MedMira’s VYRA Covid-19 is the fastest and most reliable answer.”

In the coming weeks, the diagnostics company expects to receive a CE mark for the REVEALCOVID-19 Nab-Y Neutralising Antibody Test and VYRA CoV2Flu.

Upon receipt of the CE mark, MedMira will be able to provide a complete set of Covid-19 related products to its distribution partners.

In February, the company received the CE mark for its REVEALCOVID-19 PLUS Total Antibody Test, which has been designed to identify the presence of total antibodies.